Quince Therapeutics: Funding, Investors & Team (Oct 2026)
Quince Therapeutics is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Quince Therapeutics is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currently testing several potential lead therapeutics in preclinical studies.
Quince Therapeutics has raised $115M across 1 funding round on record, the most recent an undisclosed round of $115M announced in May 2026.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Quince Therapeutics Company Profile and Key Stats
Latest funding round on record: May 2026.
Quince Therapeutics Funding Rounds
Quince Therapeutics Founders and Leadership Team
Contact details for the Quince Therapeutics team: 1 has a LinkedIn profile.
Start 14-day free trial →Quince Therapeutics Funding Compared to Other Biotechnology Startups
Quince Therapeutics' latest round of $115M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Quince Therapeutics in Biotechnology and South San Francisco
Companies Similar to Quince Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Quince Therapeutics Funding FAQs
What does Quince Therapeutics do?
Quince Therapeutics is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Quince Therapeutics is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currently testing several potential lead therapeutics in preclinical studies.
How much funding has Quince Therapeutics raised?
Quince Therapeutics has raised $115M across 1 round on record. The most recent is an undisclosed round of $115M announced in May 2026.
When did Quince Therapeutics last raise funding?
Quince Therapeutics' most recent funding round on record is an undisclosed round of $115M, announced in May 2026.
Who founded Quince Therapeutics?
FundedIQ lists Dirk Thye (Founder) at Quince Therapeutics.
Where is Quince Therapeutics headquartered?
Quince Therapeutics is based in South San Francisco, California, United States.
How many employees does Quince Therapeutics have?
Quince Therapeutics is in the 11-50 employee band.
How does Quince Therapeutics' funding compare to other Biotechnology startups?
Quince Therapeutics' latest round of $115M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Quince Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Quince Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.